AXQ Capital LP Boosts Stock Position in Abbott Laboratories $ABT

Key Points

• AXQ Capital LP increased its Abbott Laboratories position by 905.1% in the second quarter, ending with 40,657 shares valued at approximately $3.69 million. Institutional investors collectively own 75.18% of Abbott’s stock.
• Abbott reported quarterly EPS of $1.31, exceeding estimates by $0.03, while revenue rose 13% year over year to $12.59 billion. The company issued third-quarter 2026 EPS guidance of $1.38–$1.46 and full-year guidance of $5.45–$5.60.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $119.50, compared with the stock’s reported price of $108.29. Abbott also pays a quarterly dividend of $0.63 per share, yielding about 2.3% annually.

AXQ Capital LP increased its position in Abbott Laboratories (NYSE:ABT - Free Report) by 905.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 40,657 shares of the healthcare product maker's stock after acquiring an additional 36,612 shares during the quarter. AXQ Capital LP's holdings in Abbott Laboratories were worth $3,689,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. J. Stern & Co. LLP boosted its stake in Abbott Laboratories by 12,439.6% during the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker's stock valued at $4,926,279,000 after buying an additional 39,005,451 shares during the last quarter. Norges Bank bought a new stake in Abbott Laboratories in the fourth quarter worth $2,938,892,000. Bank of America Corp DE purchased a new stake in Abbott Laboratories during the second quarter valued at $1,603,607,000. Legal & General Group Plc bought a new position in Abbott Laboratories during the second quarter valued at $1,082,524,000. Finally, Flossbach Von Storch SE bought a new position in Abbott Laboratories during the second quarter valued at $902,938,000. Hedge funds and other institutional investors own 75.18% of the company's stock.

Abbott Laboratories Stock Down 0.0%

NYSE:ABT opened at $108.29 on Monday. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The firm has a market cap of $187.38 billion, a PE ratio of 35.05, a price-to-earnings-growth ratio of 2.01 and a beta of 0.59. The company has a 50-day moving average of $104.43 and a 200 day moving average of $100.03.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.28 by $0.03. The firm had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company's quarterly revenue was up 13.0% on a year-over-year basis. During the same period last year, the firm earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, research analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories's payout ratio is 81.55%.

Analyst Upgrades and Downgrades

ABT has been the subject of a number of recent research reports. Bank of America dropped their target price on Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. JPMorgan Chase & Co. increased their price target on Abbott Laboratories from $110.00 to $120.00 and gave the company an "overweight" rating in a report on Friday, July 17th. Robert W. Baird initiated coverage on shares of Abbott Laboratories in a report on Wednesday, July 1st. They set an "outperform" rating and a $121.00 price target on the stock. Wolfe Research raised shares of Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 price objective on the stock in a research report on Thursday, August 13th. Finally, Citigroup increased their price target on Abbott Laboratories from $108.00 to $112.00 and gave the stock a "buy" rating in a report on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $119.50.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source